Atlas Trials

A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Clinical trial NCT03414229 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03414229
Sponsor
Memorial Sloan Kettering Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Sarcoma
Start date
2018-01-23
Primary completion
2024-09-09
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.